Valneva’s not too late in COVID-19 as analysts eye $1.1B in 2022 vaccine sales
TrustVaccines
via FiercePharma: Vaccines https://ift.tt/2zKtXvv
June 3, 2021 at 08:53AM
Valneva’s not too late in COVID-19 as analysts eye $1.1B in 2022 vaccine sales
Welcome to vaccine education 